Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


Revenue 2017


The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Zytiga was produced by Janssen.

Taking a strategic approach

Taking a strategic approach But in oncology Zytiga (abiraterone) was last year not recommended for an early use indication in final draft guidance from NICE, but that appraisal process is currently on hold after Janssen

Astellas’ Xtandi cancer drug rejected by NICE

Astellas’ Xtandi cancer drug rejected by NICE England's pricing watchdog also currently recommends the chemotherapy agent docetaxel for the treatment of hormone-refractory metastatic prostate cancer, and Janssen's Zytiga (abiraterone) for certain patients with metastatic prostate

Prostate cancer treatment market to treble to £8.2bn by 2023

Prostate cancer treatment market to treble to £8.2bn by 2023 Canada – and is expected to be driven by a rapidly ageing population, the introduction of nine premium-priced therapies and the proposed label extensions for Zytiga and Xtandi the treatment of ... Mudbhary continued: “Zytiga is anticipated to lose

Pharma deals in February 2015

Pharma deals in February 2015 Challenges associated with turning this asset around e.g. complex production, sky-high price tag, looming competition from oral rivals Xtandi (Astellas) and Medivation) and Zytiga (J&J) will be daunting.

Sovaldi pushes Gilead to the top of US pharma list

Sovaldi pushes Gilead to the top of US pharma list The firm's drugs unit Janssen was bolstered by an array of new and diverse products, including its new hep C drug Olysio (simeprevir) and prostate cancer pill Zytiga (abiraterone acetate),

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs


Add my company
11 London

The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...

Latest intelligence

Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
Senior Analytics Specialist joins Research Partnership...